lymphoproliferative disorder
Showing 1 - 25 of >10,000
Post-transplant Lymphoproliferative Disorder Trial in Saint Louis (Polatuzumab vedotin, Rituximab, CHP)
Not yet recruiting
- Post-transplant Lymphoproliferative Disorder
- Polatuzumab vedotin
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Sep 9, 2023
Post-transplant Lymphoproliferative Disorder Trial in Cleveland (Rituximab, Acalabrutinib, CT scans)
Active, not recruiting
- Post-transplant Lymphoproliferative Disorder
- Rituximab
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Jan 16, 2023
Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Recruiting
- Benign Lymphoproliferative Disorder
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Liquid Biopsy to Enable Diagnostics and Monitoring for
Recruiting
- Lymphoproliferative Disorders
- Lymphoproliferative Disorder Following Transplantation
- Liquid biopsy
-
Basel, Switzerland
- +5 more
Mar 24, 2023
Recurrent Lymphoproliferative Disorder, Refractory Lymphoproliferative Disorder Trial in Duarte (Leflunomide)
Active, not recruiting
- Recurrent Lymphoproliferative Disorder
- Refractory Lymphoproliferative Disorder
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 7, 2022
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial
Not yet recruiting
- Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
- Polymorphic Post-Transplant Lymphoproliferative Disorder
- Biopsy
- +5 more
-
New Brunswick, New Jersey
- +2 more
Mar 23, 2023
Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder Trial run by the NCI (Nivolumab)
Recruiting
- Epstein-Barr Virus Infections
- +3 more
- Nivolumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 24, 2023
Epstein-Barr Virus Infection moniToring in renAl Transplant
Recruiting
- EBV Infection
- +3 more
- EBV DNA in whole blood and plasma
-
Aarhus, Central Region Denmark, Denmark
- +2 more
Dec 12, 2022
Accuracy Evaluation of the IdentiClone Dx IGH Assay
Not yet recruiting
- B-Cell Lymphoproliferative Disorder
- IdentiClone Dx IGH (IC IGH Dx) Assay
-
San Diego, California
- +2 more
Oct 30, 2023
Lymphoma Trial in Stanford (rituximab)
Completed
- Lymphoma
- rituximab
-
Stanford, CaliforniaStanford University Medical Center
May 25, 2022
Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma Trial run by the NCI (Interferon, Rituxan and
Recruiting
- Lymphomatoid Granulomatosis
- +3 more
- Interferon
- Rituxan and EPOCH
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Seattle
Not yet recruiting
- Post-Transplant Lymphoproliferative Disorder
- +10 more
- Loncastuximab Tesirine
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 6, 2022
Early Detection of Epstein-Barr Virus Related Disease.
Active, not recruiting
- Post-transplant Lymphoproliferative Disorder
- +8 more
-
Aarhus, Central Region Of Denmark, DenmarkAarhus University Hospital
Dec 12, 2022
Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder Trial in Boston (Pirtobrutinib, Venetoclax, Allopurinol)
Not yet recruiting
- Waldenstrom Macroglobulinemia
- B-Cell Lymphoproliferative Disorder
- Pirtobrutinib
- +2 more
-
Boston, Massachusetts
- +2 more
Feb 18, 2023
Lymphoproliferative Disorder, HHV-8, Malignancy Trial run by the National Cancer Institute (NCI) (Etoposide, Interferon-alpha,
Active, not recruiting
- Lymphoproliferative Disorder
- +3 more
- Etoposide
- +13 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder, Lymphoma Trial in Montreal (Group A, Group B)
Recruiting
- Epstein-Barr Virus Infections
- +2 more
- Group A
- Group B
-
Montreal, Quebec, CanadaHôpital Maisonneuve-Rosemont
Apr 5, 2022
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail
Recruiting
- T-cell Lymphoma
- +30 more
- Optional Blood Sample
- Optional Nail Sample
-
Duarte, California
- +25 more
Jul 28, 2023
Epstein-Barr Virus Infections Trial in Strasbourg (Rituximab, control group)
Recruiting
- Epstein-Barr Virus Infections
- Rituximab
- control group
-
Strasbourg, FranceLes Hôpitaux Universitaires de Strasbourg
Dec 7, 2021
Brain and CNS Tumors, Chronic Myeloproliferative Disorders, Leukemia Trial in Detroit (3'-deoxy-3'-[18F]fluorothymidine)
Recruiting
- Brain and Central Nervous System Tumors
- +8 more
- 3'-deoxy-3'-[18F]fluorothymidine
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Mar 30, 2022
LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous T-Cell Lymphoma - Category, Primary Cutaneous CD8-Positive
Recruiting
- LGLL - Large Granular Lymphocytic Leukemia
- +13 more
-
Duarte, California
- +9 more
Aug 9, 2022
Posttransplant Lymphoproliferative Disorder Trial in Germany (Rituximab sc, Rituximab sc consolidation, Rituximab sc combined
Completed
- Posttransplant Lymphoproliferative Disorder
- Rituximab sc
- +3 more
-
Aachen, Germany
- +17 more
Aug 22, 2022
Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease Trial in Saint Louis (Transplant
Recruiting
- Immune Deficiency Disorders
- +13 more
- Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
-
Saint Louis, MissouriWashington University
Apr 25, 2022
Tissue, Blood, and Body Fluid Sample Collection From Hematologic
Recruiting
- Chronic Myeloproliferative Disorders
- +7 more
- biologic sample preservation procedure
- cytology specimen collection procedure
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Oct 14, 2021
Collecting and Storing Blood Samples From Patients With Cancer
Withdrawn
- Brain and Central Nervous System Tumors
- +10 more
- (no location specified)
Sep 20, 2021
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,
Recruiting
- Grade 1 Follicular Lymphoma
- +7 more
- Acalabrutinib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Dec 7, 2021